Zelboraf (vemurafenib) — United Healthcare

Initial criteria

• Diagnosis of Erdheim-Chester Disease OR Langerhans Cell Histiocytosis
• Cancer is positive for BRAF V600 mutation

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Zelboraf therapy

Approval duration

12 months